Table 5.
Estimated Linear and Logistic Regression Parameters of INSTI Use by Type of INSTI on BMI, Waist Circumference, Fasting Glucose, and Fasting LDL-C at REPRIEVE Entry
| Outcome | Overall (n = 4500) | Natal Sex = Female (n = 1040) | Natal Sex = Male (3460) | |||
|---|---|---|---|---|---|---|
| Weighted Estimate (95% CI)a,b | P Valuec | Weighted Estimate (95% CI)a,b | P Valuec | Weighted Estimate (95% CI)a,b | P Valuec | |
| Linear Regressions | ||||||
| BMI (kg/m2) | .19 | .54 | .18 | |||
| EVG vs No INSTI | 1.6 (1.1–2.2) | 3.3 (1.7–4.9) | 1.4 (0.8–1.9) | |||
| DTG vs No INSTI | 1.2 (0.7–1.7) | 2.3 (0.8–3.8) | 1.0 (0.5–1.5) | |||
| RAL vs No INSTI | 0.9 (0.1–1.6) | 2.1 (0.3–3.9) | 0.5 (−0.2 to 1.3) | |||
| Waist Circumference (cm) | .43 | .51 | .51 | |||
| EVG vs No INSTI | 4.1 (2.7 5.5) | 7.3 (3.9–10.7) | 3.5 (1.9–5.0) | |||
| DTG vs No INSTI | 3.5 (2.3–4.8) | 5.0 (1.9–8.2) | 3.3 (2.0–4.7) | |||
| RAL vs No INSTI | 2.6 (0.8–4.5) | 4.9 (1.2–8.5) | 2.1 (−0.02 to 4.2) | |||
| Fasting Glucose (mg/dL) | .13 | .49 | .10 | |||
| EVG vs No INSTI | −0.4 (−1.7 to 0.9) | 0.9 (−2.0 to 3.7) | −0.8 (−2.3 to 0.7) | |||
| DTG vs No INSTI | 0.9 (−0.4 to 2.2) | 0.5 (−3.1 to 4.1) | 0.9 (−0.4 to 2.3) | |||
| RAL vs No INSTI | −0.9 (−2.5 to 0.7) | −1.4 (−4.4 to 1.1) | −0.7 (−2.6 to 1.1) | |||
| Fasting LDL-C (mg/dL) | .04 | .21 | .01 | |||
| EVG vs No INSTI | 2.0 (−0.9 to 4.9) | −1.6 (−8.1 to 5.0) | 3.1 (−0.1 to 6.3) | |||
| DTG vs No INSTI | −1.5 (−4.1 to 1.2) | 2.7 (−3.1 to 8.6) | −2.5 (−5.4 to 0.5) | |||
| RAL vs No INSTI | −3.3 (−7.4 to 0.8) | −6.0 (−14.5 to 2.5) | −2.4 (−7.1 to 2.3) | |||
| Logistic Regressions | ||||||
| Obesity | .13 | .18 | .19 | |||
| EVG vs No INSTI | 1.8 (1.5–2.2) | 2.6 (1.7–4.0) | 1.7 (1.4–2.2) | |||
| DTG vs No INSTI | 1.5 (1.2–1.8) | 1.7 (1.1–2.5) | 1.6 (1.3–2.0) | |||
| RAL vs No INSTI | 1.3 (0.9–1.7) | 1.5 (0.9–2.6) | 1.2 (0.8–1.8) | |||
| Metabolic Syndrome | .04 | 1.0 | .02 | |||
| EVG vs No INSTI | 0.8 (0.6–1.0) | 1.2 (0.8–1.9) | 0.7 (0.5–0.9) | |||
| DTG vs No INSTI | 1.1 (0.9–1.3) | 1.3 (0.9–1.9) | 1.0 (0.8–1.3) | |||
| RAL vs No INSTI | 1.0 (0.8–1.4) | 1.3 (0.7–2.3) | 1.0 (0.7–1.4) | |||
| Hypertension | .0003 | .39 | .0004 | |||
| EVG vs No INSTI | 0.9 (0.7–1.1) | 1.0 (0.7–1.6) | 0.9 (0.7–1.1) | |||
| DTG vs No INSTI | 1.4 (1.2–1.7) | 1.4 (1.0–2.1) | 1.5 (1.2–1.8) | |||
| RAL vs No INSTI | 1.1 (0.8–1.4) | 1.0 (0.6–1.8) | 1.1 (0.8–1.5) | |||
Abbreviations: BMI, body mass index; CI, confidence interval; DTG, dolutegravir; EVG, elvitegravir; INSTI, integrase-strand transfer inhibitor; LDL-C, low-density lipoprotein cholesterol; RAL, raltegravir.
Weighted estimates are estimated using the product of inverse probability of treatment weights (IPTW) of each type of INSTI.
Covariates used to create IPTW included the following: natal sex, age, race, CD4 count, estimated glomerular filtration rate (</>90), smoking status, substance use, estrogen-containing preparations, testosterone-containing preparations, diet quality, and physical activity level. Sex-stratified regressions used re-estimated IPTW excluding natal sex.
P values represent contrast results evaluating whether INSTI effects differed by type of INSTI.